Mulders PF - Search Results

1

Prostate cancer biomarker profiles in urinary sediments and exosomes.

Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, Mulders PF, Jannink SA, Schalken JA. Dijkstra S, et al. Among authors: mulders pf. J Urol. 2014 Apr;191(4):1132-8. doi: 10.1016/j.juro.2013.11.001. Epub 2013 Nov 7. J Urol. 2014. PMID: 24211598

2

Value of biochemical markers in the management of disseminated prostatic cancer.

Mulders PF, Fernandez del Moral P, Theeuwes AG, Oosterhof GO, van Berkel HT, Debruyne FM. Mulders PF, et al. Eur Urol. 1992;21(1):2-5. doi: 10.1159/000474790. Eur Urol. 1992. PMID: 1376692

3

Tumor heterogeneity as prognostic factor in patients with low-stage (T1-3N0M0) renal-cell carcinoma.

van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM. van der Poel HG, et al. Among authors: mulders pf. Investig Urol (Berl). 1994;5:60-5. Investig Urol (Berl). 1994. PMID: 7719322 No abstract available.

4

Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma.

van der Poel HG, Mulders PF, Aalders TW, Oosterhof GO, Debruyne FM, Schalken JA. van der Poel HG, et al. Among authors: mulders pf. Anal Cell Pathol. 1994 Aug;7(2):153-70. Anal Cell Pathol. 1994. PMID: 7993825

5

Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.

Mulders PF, Meyden AP, Doesburg WH, Oosterhof GO, Debruyne FM. Mulders PF, et al. Br J Urol. 1994 Apr;73(4):403-8. doi: 10.1111/j.1464-410x.1994.tb07604.x. Br J Urol. 1994. PMID: 8199828 Clinical Trial.

6

Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumor heterogeneity.

van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM. van der Poel HG, et al. Among authors: mulders pf. Cancer. 1993 Nov 1;72(9):2667-74. doi: 10.1002/1097-0142(19931101)72:9<2667::aid-cncr2820720924>3.0.co;2-0. Cancer. 1993. PMID: 8402488

7

Treatment of advanced prostate cancer: the vaccine approach.

Mulders PF. Mulders PF. Scand J Urol Nephrol Suppl. 1999;203:41-3. doi: 10.1080/00365599950510049. Scand J Urol Nephrol Suppl. 1999. PMID: 10636569 No abstract available.

8

Targeting of adenovirus to human renal cell carcinoma cells.

Jongmans W, van den Oudenalder K, Tiemessen DM, Molkenboer J, Willemsen R, Mulders PF, Oosterwijk E. Jongmans W, et al. Among authors: mulders pf. Urology. 2003 Sep;62(3):559-65. doi: 10.1016/s0090-4295(03)00378-9. Urology. 2003. PMID: 12946777

9

Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.

van Gils MP, Stenman UH, Schalken JA, Schröder FH, Luider TM, Lilja H, Bjartell A, Hamdy FC, Pettersson KS, Bischoff R, Takalo H, Nilsson O, Mulders PF, Bangma CH. van Gils MP, et al. Among authors: mulders pf. Eur Urol. 2005 Dec;48(6):1031-41. doi: 10.1016/j.eururo.2005.06.009. Epub 2005 Jul 1. Eur Urol. 2005. PMID: 16054748 Review.

10

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.

Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Völler MC, Melchior S, Warnaar SO, Mala C, Beck J, Mulders PF. Bleumer I, et al. Among authors: mulders pf. J Urol. 2006 Jan;175(1):57-62. doi: 10.1016/S0022-5347(05)00040-6. J Urol. 2006. PMID: 16406869 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

250 results

Search Page

Filters